Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Arix Bioscience plc
  6. News
  7. Summary
    ARIX   GB00BD045071

ARIX BIOSCIENCE PLC

(ARIX)
  Report
Delayed Quote. Delayed London Stock Exchange - 08/03 08:14:44 am
177.0001 GBX   -0.28%
08/02Transaction in own shares
DJ
08/02Total Voting Rights
DJ
07/30Transaction in own shares
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Results of Annual General Meeting

06/14/2021 | 09:56am EDT
Arix Bioscience PLC (ARIX) 
Results of Annual General Meeting 
14-Jun-2021 / 14:55 GMT/BST 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
 
Arix Bioscience Plc 
 
Results of Annual General Meeting 
 
LONDON, 14 June 2021: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or the "Company"), a global venture capital 
company focused on investing and building breakthrough biotech companies, today announces that its Annual General 
Meeting (the "Meeting") was held today, Monday, 14 June 2021, at 14.00 BST. At the Meeting, the ordinary and special 
resolutions set out in the Notice of the Annual General Meeting dated 18 May 2021 (the "Notice of AGM"), were proposed 
and passed by way of a poll. Resolutions 1 to 10 were passed as ordinary resolutions. Resolutions 11 to 14 were passed 
as special resolutions. 
 
Full details of the poll results are set out below and will also be available on the Company's website. 
 
                                                                            VOTES            TOTAL      % of  VOTES 
No            RESOLUTION                                  VOTES FOR  %      AGAINST   %      VOTES      ISC   WITHHELD 
                                                                                                        VOTED 
              To receive the Directors' Report and the 
1             accounts of the Company for the year ended  61,517,202 92.76% 4,800,657 7.24%  66,317,859 50.32 2,783 
              31 December 2020 
2             To approve the Directors' Remuneration      58,196,535 92.34% 4,825,953 7.66%  63,022,488 47.82 3,298,154 
              Report 
3             To re-elect Giles Kerr as a Director        61,344,286 92.51% 4,964,902 7.49%  66,309,188 50.31 11,454 
4             To elect Peregrine Moncreiffe as a Director 60,271,773 92.55% 4,855,144 7.45%  65,126,917 49.42 1,193,725 
5             To elect Maureen O'Connell as a Director    58,841,750 90.36% 6,274,013 9.64%  65,115,763 49.41 1,204,879 
6             To elect Isaac Kohlberg as a Director       58,842,050 90.35% 6,285,167 9.65%  65,127,217 49.42 1,193,425 
7             To elect Robert Lyne as a Director          60,072,787 90.59% 6,236,701 9.41%  66,309,488 50.31 11,154 
8             To appoint BDO LLP as auditors of the       61,500,167 92.74% 4,817,701 7.26%  66,317,868 50.32 2,774 
              Company 
              To authorise the Audit and Risk Committee 
9             of the Company to fix the remuneration of   61,516,153 92.76% 4,804,189 7.24%  66,320,342 50.32 300 
              the auditors 
10            To authorise the Directors to allot shares  61,019,094 92.01% 5,297,239 7.99%  66,316,333 50.32 4,309 
11            Authority to disapply statutory pre-        59,364,402 89.52% 6,951,931 10.48% 66,316,333 50.32 4,309 
              emption rights* 
12            Additional authority to disapply statutory  59,363,555 89.52% 6,952,778 10.48% 66,316,333 50.32 4,309 
              pre- emption rights* 
13            To authorise the Company to purchase its    61,478,596 92.71% 4,836,857 7.29%  66,315,453 50.32 5,189 
              own shares* 
              Authority to call a general meeting, other 
14            than an annual general meeting, on not less 61,517,295 92.76% 4,803,047 7.24%  66,320,342 50.32 300 
              than 14 clear days' notice* 

*Special resolutions

In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

The full text of the resolutions considered at the AGM are contained in the Notice of AGM, published on 18 May 2021, which is available on Arix investor relations website.

A replay of the presentation and the Meeting will be available via webcast shortly after the event on the Company's investor relations website at: https://arixbioscience.com/investor-relations/events-presentations

[ENDS]

For more information on Arix, please contact:

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Shabnam Bashir

+44 (0)20 3922 1906

optimum.arix@optimumcomms.com

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com -----------------------------------------------------------------------------------------------------------------------

ISIN:           GB00BD045071 
Category Code:  RAG 
TIDM:           ARIX 
LEI Code:       213800OVT3AHQCXNIX43 
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State 
Sequence No.:   111187 
EQS News ID:    1207766 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------
 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1207766&application_name=news 
 

(END) Dow Jones Newswires

June 14, 2021 09:55 ET (13:55 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
ARIX BIOSCIENCE PLC -0.28% 177.0001 Delayed Quote.-18.95%
DJ INDUSTRIAL -0.18% 34750.22 Delayed Quote.14.14%
All news about ARIX BIOSCIENCE PLC
08/02Transaction in own shares
DJ
08/02Total Voting Rights
DJ
07/30Transaction in own shares
DJ
07/28Transaction in own shares
DJ
07/27UPDATE : IP Group's Artios Pharma Raises $153 Million To Fund Cancer Treatment D..
MT
07/27Artios raises USD153m in Series C financing -2-
DJ
07/27Artios raises USD153m in Series C financing
DJ
07/26Transaction in own shares
DJ
07/23Transaction in own shares
DJ
07/21Notice of Results
DJ
More news
Financials
Sales 2021 0,50 M 0,70 M 0,70 M
Net income 2021 37,7 M 52,5 M 52,5 M
Net cash 2021 175 M 244 M 244 M
P/E ratio 2021 6,14x
Yield 2021 -
Capitalization 223 M 310 M 311 M
EV / Sales 2021 96,3x
EV / Sales 2022 105x
Nbr of Employees 12
Free-Float 72,3%
Chart ARIX BIOSCIENCE PLC
Duration : Period :
Arix Bioscience plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARIX BIOSCIENCE PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 177,50 GBX
Average target price 221,50 GBX
Spread / Average Target 24,8%
EPS Revisions
Managers and Directors
Robert William Henry Lyne CEO, COO, Secretary, Director & General Counsel
Marcus Karia Group Finance Director
Peregrine D. E. M. Moncreiffe Non-Executive Chairman
Graeme Smith Chief Technology Officer
Giles Francis Bertram Kerr Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
ARIX BIOSCIENCE PLC-18.95%310
INVESTOR AB (PUBL)43.73%76 664
CK HUTCHISON HOLDINGS LIMITED5.73%28 320
AB INDUSTRIVÄRDEN (PUBL)25.24%17 153
HAL TRUST29.01%15 304
LIFCO AB (PUBL)62.74%13 571